Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
A phase 2 trial of Denileukin diftitox in Melanoma and Advanced melanoma, run by Eisai Inc., completed.
Overview
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma is a phase 2 interventional study registered as NCT01127451 by Eisai Inc., with 75 participants recorded, started 2010-06-22 and reaching its primary completion in 2015-04-07. Interventions recorded: Denileukin diftitox. Conditions recorded: Stage IIIC Melanoma, Stage IV Melanoma.
Linked to the drug Denileukin diftitox because the registry names it among its interventions and Melanoma and Advanced melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialPhase II Trial of Ontak With Metastatic Melanoma
Shares Denileukin diftitox, Melanoma and the tag pipeline.
- TrialA Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
Shares Denileukin diftitox and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
- TrialAMT-253 in Patients With Advanced Solid Tumours
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
- TrialA Study of ST-1898 for Unresectable or Metastatic Melanoma
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
- TrialSCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.